Work

HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings

Year: 2025

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2024.7351

Authors: Samuel Crawford, Huimin Li, Bhavini Srivastava, Pam Martin, James Gahn, Shaffee Bacchus, Olga Ryan, Monika Salkar

Institutions: AbbVie (United States), Medical Decision Modeling (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4408938970

FWCI: 0.531

Cites:

Cited by: 1

Related to: 10